Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning. Today, we see fallout from the FDA’s rejection of Replimune’s melanoma drug affecting another biotech, learn how Sarepta’s decision-making has affected a patient population that hasn’t always been in the headlines, and more.
As Sarepta fights for Duchenne therapy, another group of patients feels left behind
Sarepta Therapeutics is fighting to salvage its Duchenne therapy Elevidys amid safety setbacks. But families of children with another condition, limb-girdle muscular dystrophy, say they’ve been abandoned by the company, which recently scrapped nearly a decade of work on gene therapies for the disease.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
